Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

BioKey Q3 2026 Results: Net Loss of $398K, Loss Widens

BioKey (Cayman), Inc. reported zero revenue for the nine months ended September 30, 2026, with a net loss of $873,721 compared to $538,188 in the prior year period. The company remains heavily dependent on recurring loans from ABVC BioPharma, Inc. to support its operations, with total liabilities reaching $7.56 million against total assets of $1.61 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-0.4-0.2
Net income-0.4-0.2
EPS (diluted, $ a share)$-0.01$-0.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

BioKey (Cayman), Inc.: key numbers

Shares outstanding
30MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.